Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement

Core Viewpoint - Azitra, Inc. has received a notice of non-compliance from NYSE American regarding its stockholders' equity, which must meet specific requirements to maintain its listing status [1] Compliance Issues - Azitra is not in compliance with the NYSE American's continued listing standards under Section 1003(a)(iii), which requires stockholders' equity of $6 million or more due to reported losses [1] - Previously, on October 1, 2025, Azitra was notified of non-compliance with Section 1003(a)(ii), which requires a minimum stockholders' equity of $4 million if losses were reported in three of the last four fiscal years [1] - The company submitted a plan to regain compliance by April 1, 2027, which was accepted on December 16, 2025 [1] Timeline and Consequences - Azitra has until April 1, 2027, to regain compliance with the NYSE American's listing standards; failure to do so may result in delisting proceedings [1] - The company will remain listed during the compliance plan period and will undergo periodic reviews, including quarterly monitoring [1] Financial Health - The notice from the Exchange does not immediately affect the trading of Azitra's common stock or its business operations [1] - Azitra's audited financial statements for the year ended December 31, 2025, included a substantial doubt regarding the company's ability to continue as a going concern [1] Business Focus - Azitra is a clinical stage biopharmaceutical company focused on precision dermatology, with its lead program ATR-12 aimed at treating Netherton syndrome, a rare skin disease [1] - The company also has an advanced program ATR-04 for treating EGFR inhibitor-associated rash, which has received Fast Track designation from the FDA [1] - Azitra's proprietary platform includes a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning technology [1]